Tag: Repatha

The European Commission authorise use of evolocumab to reduce risk of...

The European Commission (EC) has authorised a new indication in the evolocumab (Repatha, Amgen) label for adults with established atherosclerotic cardiovascular disease—myocardial infarction, stroke...

EBBINGHAUS trial shows non-inferiority of evolocumab for cognitive function in cardiovascular...

Amgen has announced detailed results from the evolocumab (Repatha) cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in...

ACC 2017: PCSK9 inhibitor evolocumab significantly reduces the risk of cardiovascular...

Data for a new drug that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) show that it is associated with a near 60% reduction in...

Evolocumab significantly reduces risk of cardiovascular events

The FOURIER trial evaluating whether evolocumab (Repatha, Amgen) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) has...

AHA 2016: Two thirds of patients experience plaque regression with the...

Amgen has announced that adding its PCSK9 inhibitor evolocumab (Repatha) to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with...

Positive top-line results from phase 3 GLAGOV imaging study of evolocumab

The Phase 3 GLAGOV (Global assessment of plaque regression with a PCSK9 antibody as measured by intravascular iltrasound) trial has met both its primary...